On April 29, 2020 Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that an abstract for its ongoing Phase II study of oral paclitaxel and encequidar (Oral Paclitaxel; formerly known as Oraxol), for the treatment of angiosarcoma, has been accepted for presentation in a poster discussion session at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) upcoming ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program, to be held from May 29 to May 31, 2020 (Press release, Athenex, APR 29, 2020, View Source [SID1234573878]).
Presentation details are as follows:
Title: (Abstract 11517) A Phase II Study of Oraxol in the Treatment of Unresectable Cutaneous Angiosarcoma
Poster Session: Sarcoma
Location: ASCO (Free ASCO Whitepaper) Virtual Scientific Program
This Phase II study is an ongoing, single arm study evaluating the activity, safety and tolerability of oral paclitaxel (205 mg/m2) with encequidar administered orally, once daily, for 3 consecutive days per week in patients with cutaneous angiosarcoma (clinicaltrials.gov identifier: NCT03544567).
The abstract title is currently available on the ASCO (Free ASCO Whitepaper) Meeting Library, with the full abstract scheduled to be published on May 13, 2020, at 5:00 PM EDT.
The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.
Angiosarcomas are a type of soft tissue sarcoma characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood and lymphatic vessels. Angiosarcomas arise in various body sites, including cutaneous, soft tissue, and visceral locations. Angiosarcomas are frequently metastatic at diagnosis, with a natural history complicated by local recurrence, distant metastases, and poor overall survival. There is no approved treatment for angiosarcoma and survival is limited with treatments currently available. However, reports in the literature of objective tumor response support the use of intravenous paclitaxel in the treatment of angiosarcoma.